These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6145436)

  • 1. Haemodynamic effects of ICI 118,587 in cardiomyopathy.
    Simonsen S
    Br Heart J; 1984 Jun; 51(6):654-7. PubMed ID: 6145436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acute effect of the cardioselective beta-1-partial agonist, Corwin, on ventricular function and myocardial oxygen consumption in patients with dilated cardiomyopathy].
    Amende I; Simon R; Hood WP; Lichtlen PR
    Z Kardiol; 1986 May; 75(5):291-5. PubMed ID: 2874668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
    Pouleur H; Hanet C; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction.
    Molajo AO; Bennett DH
    Br Heart J; 1985 Jul; 54(1):17-21. PubMed ID: 2861834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the beta 1-adrenergic receptor partial agonist xamoterol on left ventricular diastolic function. An evaluation after 1-6 years of oral therapy.
    Pouleur H; Etienne J; Van Mechelen H; Gurné O; Rousseau MF
    Circulation; 1990 Feb; 81(2 Suppl):III87-92. PubMed ID: 1967560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.
    Heng MK
    Clin Cardiol; 1990 Mar; 13(3):171-6. PubMed ID: 1969783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective beta-1-adrenoceptor partial agonist treatment for congestive heart failure.
    Shabetai R
    Cardiology; 1990; 77(5):357-66. PubMed ID: 1981492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hemodynamic and metabolic effects of ICI 118,587 (Corwin), a selective partial beta 1 agonist, in patients with dilated cardiomyopathy.
    Bhatia SJ; Swedberg K; Chatterjee K
    Am Heart J; 1986 Apr; 111(4):692-6. PubMed ID: 2869673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term studies with xamoterol in heart failure.
    Waller DG
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):53S-58S. PubMed ID: 2572255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.
    Pouleur H; Hanet C; Rousseau MF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):82S-83S. PubMed ID: 2572263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of beta 1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease.
    Ikäheimo MJ; Takkunen JT
    Int J Cardiol; 1984 Mar; 5(3):339-49. PubMed ID: 6231256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
    de Feyter PJ; Serruys PW; Suryapranata H
    Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction.
    Sato H; Inoue M; Matsuyama T; Ozaki H; Shimazu T; Takeda H; Ishida Y; Kamada T
    Circulation; 1987 Jan; 75(1):213-20. PubMed ID: 2878742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on diastolic dysfunction: a new approach to heart failure therapy.
    Pouleur H; Hanet C; Gurné O; Rousseau MF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):41S-52S. PubMed ID: 2572254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sympathetic modulation in practice: the German clinical experience.
    Kupper W; Erlemeier HH; Bleifeld W
    Eur Heart J; 1990 Apr; 11 Suppl A():19-25. PubMed ID: 1971586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Illustration of the effects of long-term xamoterol therapy on the time course of left ventricular pressure.
    van Mechelen H; Ries A; Pouleur H; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():67-9. PubMed ID: 1971598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.